Precision Biologics for Indianapolis medspas and aesthetic practices

Physician supervision and vendor review

Because medspas sell and use biologic products under physician supervision, the review of a new supplier typically runs through the practice's supervising physician or medical director rather than through front-desk or aesthetic staff alone. That review generally covers the distributor's licensure, the documentation available for a given lot, and whether the practice's own counsel has looked at how a product's intended use maps to the applicable regulatory framework.

• Route new supplier review through the supervising physician or medical director
• Confirm documentation availability before committing to a product line
• Separate Wharton's jelly review from exosome product review

Account verification for aesthetic practices

Precision Biologics opens accounts only for licensed professionals and requires a valid NPI number during onboarding. For a medspa or dermatology practice, the NPI tied to the supervising physician is used to verify the account before pricing is released. Pricing itself is never published and is available only once an account is verified.

Receiving shipments and lot tracking

Cryopreserved Wharton's jelly products are shipped overnight on dry ice in validated containers and should be logged on arrival against the cold-chain indicator before storage; lyophilized exosome products are shelf-stable and are handled according to the insert supplied with the lot. Precision Biologics assigns a unique identifier to every tissue lot, and practices are expected to track product use by lot at the patient record level.

Confirming regulatory standing and getting set up

Precision Biologics does not advise on clinical use, dosing, or procedures and recommends that an Indianapolis-area aesthetic practice confirm its own standing with the Indiana medical board and review the regulatory posture of any product with its own counsel before adding a Wharton's jelly or exosome line. Account setup support includes registration and licensure documentation on request and physician-level calls focused on product documentation, not clinical guidance.

These products are not FDA approved or licensed for any disease or condition. Information here is for licensed healthcare professionals and is not medical or legal advice.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.